Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer.

Butyrates and retinoids are promising antineoplastic agents. Here we analyzed effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide (4-HPR) on prostate cancer cells as monotherapy or in combination in vitro and in vivo. Sodium butyrate and 4-HPR induced concentration-dependent growth inhibition in prostate cancer cells in vitro. The isobologram analysis revealed that sodium butyrate and 4-HPR administered together antagonize effects of each other. For the in vivo studies, a water-soluble complex (4-HPR with a cyclodextrin) was created. A single dose of sodium butyrate and 4-HPR showed a peak level in chicken plasma within 30 minutes. Both compounds induced inhibition of proliferation and apoptosis in xenografts of the chicken chorioallantoic membrane. Analysis of the cytotoxic effects of the drugs used in combination demonstrated an antagonistic effect on inhibition of proliferation and on induction of apoptosis. Prolonged jun N-terminal kinase phosphorylation induced by sodium butyrate and 4-HPR was strongly attenuated when both compounds were used in combination. Both compounds induced inhibition of NF-kappaB. This effect was strongly antagonized in LNCaP cells when the compounds were used in combination. These results indicate that combinational therapies have to be carefully investigated due to potential antagonistic effects in the clinical setting despite promising results of a monotherapy.

• Publication year

  2007

• Venue

  Neoplasia

• Publication date

  2007-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1569-9056(08)60821-0PMID 17401464PMCID PMC1838581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reactive oxygen species mediate crosstalk between NF-κB and JNK

  2006cited by this paper
• Reactive oxygen species mediate crosstalk between NF-kappaB and JNK.

  2006cited by this paper
• MAP kinase pathways

  2005cited by this paper
• High-performance liquid chromatographic determination of acetyl-11-keto-alpha-boswellic acid, a novel pentacyclic triterpenoid, in plasma using a fluorinated stationary phase and photodiode array detection: application in pharmacokinetic studies.

  2005cited by this paper
• High-performance liquid chromatographic determination of acetyl-11-keto-α-boswellic acid, a novel pentacyclic triterpenoid, in plasma using a fluorinated stationary phase and photodiode array detection : Application in pharmacokinetic studies

  2005cited by this paper
• Chemotherapy for metastatic disease: current status.

  2005cited by this paper
• Reactive Oxygen Species Promote TNF -Induced Death and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases

  2005cited by this paper
• Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.

  2005cited by this paper
• Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer

  2005cited by this paper
• Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid

  2005cited by this paper
• Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

  2005cited by this paper
• Fenretinide: a p53-independent way to kill cancer cells.

  2005cited by this paper
• Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer

  2004cited by this paper
• Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action.

  2004cited by this paper
• Retinoids in cancer therapy and chemoprevention: promise meets resistance

  2003cited by this paper
• Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

  2003cited by this paper
• Reprints and Subscriptions Permissions

  2003cited by this paper
• Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?

  2003cited by this paper
• Contributions of mitogen‐activated protein kinase and nuclear factor kappa B to N‐(4‐hydroxyphenyl)retinamide–induced apoptosis in prostate cancer cells

  2002cited by this paper
• Drug synergism: its detection and applications.

  2001cited by this paper
• Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells.

  2001cited by this paper
• Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model.

  2001cited by this paper
• Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration.

  2000cited by this paper
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

  2000cited by this paper
• Tributyrin induces differentiation, growth arrest and apoptosis in androgen‐sensitive and androgen‐resistant human prostate cancer cell lines

  2000cited by this paper
• Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells.

  1999cited by this paper
• N‐(4‐hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells

  1994cited by this paper
• Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer

  1993cited by this paper
• Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.

  1993cited by this paper
• Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide.

  1993cited by this paper
• Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.

  1991cited by this paper
• LNCaP model of human prostatic carcinoma.

  1983cited by this paper
• Inhibition of I (cid:1) B Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in Vivo

  year unknowninfluential reference

• Microbiota-derived metabolites in tumorigenesis: mechanistic insights and therapeutic implications

  2025cites this paper
• The chorioallantoic membrane as a bio-barrier model for the evaluation of nanoscale drug delivery systems for tumour therapy.

  2021cites this paper
• Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via Targeting Pyruvate Kinase M2 and Metabolic Reprogramming *

  2018cites this paper
• Special Issue: Cancer Metabolism

  2017cites this paper
• Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases

  2017cites this paper
• Real-time quantitative PCR array to study drug-induced changes of gene expression in tumor cell lines

  2017cites this paper
• A computational investigation of the photochemical oxaziridine and amide conversion process of open-chain conjugated nitrone with electron-withdrawing trifluoromethyl group on nitrogen

  2015cites this paper
• Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism

  2014cites this paper
• Impact of IGF system on dietary short chain fatty a cid-induced anti- inflammatory and anti-tumor effects.

  2012cites this paper
• Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells

  2011cites this paper
• Efficacy of butyrate analogues in HT‐29 cancer cells

  2010cites this paper
• Structure–activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT‐116 human colorectal cancer cells

  2010cites this paper
• RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

  2009cites this paper
• Liposome-mediated therapy of neuroblastoma.

  2009cites this paper
• The War on Cancer rages on.

  2009cites this paper
• The War on Cancer Rages On The War on Cancer Rages On

  2009cites this paper
• MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours

  2008cites this paper
• Neoplasia: the second decade.

  2008cites this paper
• Neoplasia: An Anniversary of Progress.

  2007cites this paper
• [Research at the Ulm University in prostate cancer].

  2007cites this paper
• Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells.

  2007cites this paper